Studies related to Lung Function and Saffron

An Evaluation Of The Effect Of Saffron Supplementation On The Antibody Titer To Heat-shock Protein (HSP) 70, HsCRP And Spirometry Test In Patients With Mild And Moderate Persistent Allergic Asthma: A Triple-blind, Randomized Placebo-controlled Trial

Effect Increase
Values FEV1. Placebo: before 76.40 ± 10.48, after 73.21 ± 12.15. Saffron: before 76.02 ± 10.92, after 80.15 ± 12.59. FVC. Placebo: before 81.12 ± 11.68, after 79.73 ± 12.65. Saffron: before 81.97 ± 12.93, after 84.31 ± 12.99. FEV1/FVC. Placebo: before 94.12 ± 7.16, after 91.57 ± 8.75. Saffron: before 93.10 ± 7.88, after 94.86 ± 9.18. FEF25-75 Placebo: before 62.37 ± 16.87, after 58.65 ± 19.79. Saffron: before 63.65 ± 19.42, after 68.26 ± 23.95.
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 80
Sex Both Genders
Age Range 18-29, 30-44, 45-64
Notes for this study:
In a randomized, triple-blind, placebo-controlled trial, 80 participants with mild or moderate allergic asthma took 100 mg of saffron or placebo for 8 weeks.

The primary outcome was lung function as measured by spirometry and FEV1, FVC, FEV1/FVC ratio, and FEF25-75 were improved. Hs-CRP was dramatically reduced and anti-HSP70 antibodies were reduced somewhat in the saffron group while they were increased in the placebo group, the difference being statistically significant.

The trial was preregistered: IRCT2017012132081N2